Banco Santander S.A. Raises Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Banco Santander S.A. increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 51.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,959 shares of the company’s stock after acquiring an additional 667 shares during the period. Banco Santander S.A.’s holdings in Medpace were worth $654,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Ashton Thomas Securities LLC acquired a new stake in Medpace in the 3rd quarter valued at about $37,000. DT Investment Partners LLC acquired a new stake in Medpace in the second quarter valued at approximately $41,000. Capital Performance Advisors LLP purchased a new position in Medpace in the third quarter worth approximately $46,000. Ashton Thomas Private Wealth LLC acquired a new position in Medpace during the 2nd quarter worth approximately $52,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of Medpace in the 1st quarter valued at approximately $54,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Truist Financial cut their price target on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. UBS Group downgraded shares of Medpace from a “buy” rating to a “neutral” rating and dropped their target price for the company from $420.00 to $350.00 in a research report on Friday, September 27th. TD Cowen reduced their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Robert W. Baird lowered Medpace from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $413.00 to $349.00 in a report on Wednesday, October 23rd. Finally, StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $380.00.

Medpace Trading Down 1.2 %

Medpace stock opened at $337.75 on Friday. The stock has a market capitalization of $10.50 billion, a price-to-earnings ratio of 29.58, a PEG ratio of 1.89 and a beta of 1.37. The stock has a 50 day moving average of $340.42 and a two-hundred day moving average of $373.77. Medpace Holdings, Inc. has a twelve month low of $268.80 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. The firm had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Medpace’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period last year, the firm posted $2.22 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.